

Ritu Salani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6657638/publications.pdf>

Version: 2024-02-01

100
papers

4,422
citations

117453

34
h-index

110170

64
g-index

101
all docs

101
docs citations

101
times ranked

7534
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
2	Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 466-478.	0.7	343
3	Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 1460-1466.	0.8	243
4	Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1810-1818.	0.8	229
5	Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. <i>Gynecologic Oncology</i> , 2016, 143, 3-15.	0.6	208
6	An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. <i>Gynecologic Oncology</i> , 2017, 146, 3-10.	0.6	201
7	Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer. <i>Cancer</i> , 2007, 109, 685-691.	2.0	135
8	Amplicon profiles in ovarian serous carcinomas. <i>International Journal of Cancer</i> , 2007, 120, 2613-2617.	2.3	124
9	A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 18739-18744.	3.3	121
10	NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 888-895.	2.3	113
11	Cancer and pregnancy: an overview for obstetricians and gynecologists. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 7-14.	0.7	98
12	BRCA mutation in ovarian cancer: testing, implications and treatment considerations. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 519-531.	1.4	96
13	Do survivorship care plans impact patients' evaluations of care? A randomized evaluation with gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2013, 129, 554-558.	0.6	83
14	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
15	Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. <i>Gynecologic Oncology</i> , 2017, 146, 588-595.	0.6	77
16	Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 108, 271-275.	0.6	75
17	Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer. <i>Clinical Therapeutics</i> , 2016, 38, 449-458.	1.1	73
18	Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 144, 459-467.	0.6	61

#	ARTICLE	IF	CITATIONS
19	Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 60.e1-60.e7.	0.7	58
20	Life after endometrial cancer: A systematic review of patient-reported outcomes. <i>Gynecologic Oncology</i> , 2018, 148, 403-413.	0.6	54
21	Diagnosis and Management of Adenocarcinoma in Situ. <i>Obstetrics and Gynecology</i> , 2020, 135, 869-878.	1.2	54
22	Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: A case-control study. <i>Gynecologic Oncology</i> , 2007, 107, 495-499.	0.6	51
23	Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). <i>Gynecologic Oncology</i> , 2019, 153, 496-499.	0.6	50
24	Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 121, 269-272.	0.6	49
25	Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. <i>Gynecologic Oncology</i> , 2017, 147, 110-114.	0.6	46
26	Ovarian cancer specific kallikrein profile in effusions. <i>Gynecologic Oncology</i> , 2007, 105, 501-507.	0.6	45
27	Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2007, 106, 476-481.	0.6	45
28	Subdividing Ovarian and Peritoneal Serous Carcinoma Into Moderately Differentiated and Poorly Differentiated Does not Have Biologic Validity Based on Molecular Genetic and In Vitro Drug Resistance Data. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1667-1674.	2.1	42
29	Recurrence patterns and surveillance for patients with early stage endometrial cancer. <i>Gynecologic Oncology</i> , 2011, 123, 205-207.	0.6	42
30	Annexin XI Is Associated with Cisplatin Resistance and Related to Tumor Recurrence in Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2007, 13, 6842-6849.	3.2	39
31	Survivorship planning in gynecologic cancer patients. <i>Gynecologic Oncology</i> , 2013, 130, 389-397.	0.6	38
32	Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , 2019, 133, 245-254.	1.2	38
33	The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2013, 128, 44-48.	0.6	37
34	Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184. <i>Gynecologic Oncology</i> , 2010, 119, 538-542.	0.6	35
35	Surgical Management of Mesenteric Lymph Node Metastasis in Patients Undergoing Rectosigmoid Colectomy for Locally Advanced Ovarian Carcinoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 3552-3557.	0.7	33
36	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31

#	ARTICLE	IF	CITATIONS
37	Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. <i>Gynecologic Oncology</i> , 2016, 143, 294-301.	0.6	31
38	Incorporating resident/fellow training into a robotic surgery program. <i>Journal of Surgical Oncology</i> , 2015, 112, 684-689.	0.8	30
39	Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. <i>Maturitas</i> , 2021, 144, 37-44.	1.0	30
40	Neuroendocrine carcinoma of the uterine cervix: The role of multimodality therapy in early-stage disease. <i>Gynecologic Oncology</i> , 2013, 129, 135-139.	0.6	28
41	Expression of Extracellular Matrix Proteins in Ovarian Serous Tumors. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 141-146.	0.9	27
42	Swelling Among Women Who Need Education About Leg Lymphedema: A Descriptive Study of Lymphedema in Women Undergoing Surgery for Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1507-1512.	1.2	27
43	Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. <i>Gynecologic Oncology</i> , 2019, 152, 316-321.	0.6	27
44	Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1361-1371.	1.2	26
45	Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?. <i>Gynecologic Oncology</i> , 2014, 135, 95-99.	0.6	25
46	The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 119, 491-495.	0.6	24
47	Surgical Management of Epithelial Ovarian Cancer. <i>Clinical Obstetrics and Gynecology</i> , 2012, 55, 75-95.	0.6	24
48	Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. <i>Gynecologic Oncology</i> , 2021, 160, 161-168.	0.6	24
49	Transverse colectomy in ovarian cancer surgical cytoreduction: Operative technique and clinical outcome. <i>Gynecologic Oncology</i> , 2008, 109, 364-369.	0.6	22
50	Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin. <i>Gynecologic Oncology</i> , 2014, 135, 90-94.	0.6	22
51	Ovarian effects of radiation and cytotoxic chemotherapy damage. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2019, 55, 37-48.	1.4	22
52	Measurement of Cyclin E Genomic Copy Number and Strand Length in Cell-Free DNA Distinguish Malignant versus Benign Effusions. <i>Clinical Cancer Research</i> , 2007, 13, 5805-5809.	3.2	21
53	Reducing readmissions after robotic surgical management of endometrial cancer:A potential for improved quality care. <i>Gynecologic Oncology</i> , 2013, 131, 508-511.	0.6	20
54	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19

#	ARTICLE	IF	CITATIONS
55	Time to consider integration of a formal robotic-assisted surgical training program into obstetrics/gynecology residency curricula. <i>Journal of Robotic Surgery</i> , 2018, 12, 517-521.	1.0	18
56	Uterine Torsion and Fetal Bradycardia Associated With External Cephalic Version. <i>Obstetrics and Gynecology</i> , 2006, 108, 820-822.	1.2	17
57	A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2012, 125, 158-162.	0.6	17
58	Feasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer—A Phase 1 Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 682-686.	1.2	16
59	A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 262-266.	0.6	16
60	The Impact of Burnout on the Obstetrics and Gynecology Workforce. <i>Clinical Obstetrics and Gynecology</i> , 2019, 62, 444-454.	0.6	16
61	Guideline-concordant treatment is associated with improved survival among women with non-endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 157, 716-722.	0.6	16
62	Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 150, 119-126.	0.6	15
63	Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062). <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2363-2370.	1.9	15
64	Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2019, 152, 554-559.	0.6	14
65	Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?. <i>Gynecologic Oncology</i> , 2017, 144, 290-293.	0.6	13
66	Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. <i>Gynecologic Oncology</i> , 2018, 151, 501-505.	0.6	13
67	Gynecologic care for breast cancer survivors: assisting in the transition to wellness. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 390-397.	0.7	12
68	Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. <i>Gynecologic Oncology</i> , 2019, 155, 69-74.	0.6	10
69	Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 255-258.	0.6	10
70	Feasibility of implementing a text-based symptom-monitoring program of endometrial, ovarian, and breast cancer patients during treatment. <i>Quality of Life Research</i> , 2021, 30, 3241-3254.	1.5	10
71	Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?. <i>Gynecologic Oncology</i> , 2012, 127, 362-366.	0.6	9
72	Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center. <i>Gynecologic Oncology</i> , 2015, 138, 689-693.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI. <i>Gynecologic Oncology</i> , 2016, 140, 405-408.	0.6	9
74	Training the Next Generation of Robotic Surgeons Using Guided Mentorship: A Randomized Controlled Trial. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 1075-1079.	0.3	8
75	Predicting Inpatient Stay Lasting 2 Midnights or Longer After Robotic Surgery for Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 583-589.	0.3	7
76	Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. <i>Gynecologic Oncology</i> , 2021, 162, 619-625.	0.6	7
77	GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2019, 153, 335-342.	0.6	6
78	The Construction of Case-Specific Resident Learning Goals. <i>Journal of Surgical Education</i> , 2020, 77, 859-865.	1.2	6
79	Residents'™ method for gaining operative autonomy. <i>American Journal of Surgery</i> , 2020, 220, 893-898.	0.9	6
80	Digital Karyotyping. <i>Molecular Diagnosis and Therapy</i> , 2006, 10, 231-237.	1.6	5
81	The association between histological subtype of a first primary endometrial cancer and second cancer risk. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 290-298.	1.2	5
82	Meeting report from the 2020 Annual (virtual) Meeting of the American Society of Clinical Oncology. <i>Gynecologic Oncology</i> , 2020, 159, 13-16.	0.6	5
83	Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations. <i>Surgical Oncology</i> , 2020, 34, 40-45.	0.8	4
84	Who will be readmitted? Evaluation of the laparoscopic hysterectomy readmission score in a gynecologic oncology population undergoing robotic-assisted hysterectomy. <i>Gynecologic Oncology</i> , 2022, 164, 628-638.	0.6	4
85	Predictive value of endocervical curettage at cervical conization and provider practices in management of high-grade cervical dysplasia. <i>Journal of reproductive medicine, The</i> , 2010, 55, 129-33.	0.2	3
86	Surgical Approaches and Short-Term Surgical Outcomes for Patients with Morbid Obesity and Endometrial Cancer. <i>Journal of Gynecologic Surgery</i> , 2009, 25, 41-48.	0.0	2
87	Bariatric surgery after failed conservative management in a morbidly obese patient with endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2019, 27, 69-71.	0.3	2
88	Overview of epithelial ovarian cancer and updates in management strategies. <i>Expert Review of Obstetrics and Gynecology</i> , 2009, 4, 383-399.	0.4	1
89	Here it comes....the role of cost-effective analysis. <i>Gynecologic Oncology</i> , 2012, 127, 265-266.	0.6	1
90	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 83.	0.7	1

#	ARTICLE	IF	CITATIONS
91	Practice patterns in post-treatment surveillance in patients with primary epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 888-892.	1.2	1
92	Unwittingly biased: A note to gynecologic cancer providers. <i>Gynecologic Oncology</i> , 2021, 160, 646-648.	0.6	1
93	Changing paradigms in intermediate-risk cervical cancer: Sedlis revisited. <i>Gynecologic Oncology</i> , 2021, 162, 527-528.	0.6	1
94	Timely delivery of primary chemoradiation for the treatment of locally advanced cervical cancer: are we meeting this quality measure?. <i>Journal of Radiation Oncology</i> , 2017, 6, 189-195.	0.7	0
95	The long game: Evolution of clinical decision making throughout residency and fellowship. <i>American Journal of Surgery</i> , 2021, , .	0.9	0
96	Annual cost of wasted indocyanine green during sentinel lymph node mapping for patients with endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, S90.	0.6	0
97	Sexual morbidity, quality of life, and patient-provider communication among ovarian cancer patients and survivors. <i>Gynecologic Oncology</i> , 2021, 162, S273.	0.6	0
98	The American Society of Clinical Oncology 2021 annual (virtual) meeting: A review and summary of selected abstracts. <i>Gynecologic Oncology</i> , 2021, 162, 245-248.	0.6	0
99	Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. <i>Gynecologic Oncology</i> , 2021, 163, 392-397.	0.6	0
100	Racial disparities in surgical approach and clinical outcomes of surgically treated endometrial cancer. <i>Gynecologic Oncology</i> , 2022, 164, 5.	0.6	0